Glucuronidation is an enzymatic process that terminally inactivates steroid hormones, including estrogens and androgens, thereby influencing carcinogenesis in hormone-dependent cancers.
INTRODUCTION
Breast and prostate cancer are the most common forms of hormone-dependent cancer and account for a major proportion of cancer-related deaths in women and men, respectively. Breast cancer is predominantly driven by aberrant estrogen receptor alpha (ERα) signaling and prostate cancer by aberrant androgen receptor (AR) signaling. These diseases display multiple similarities of etiology and pathology (1) . There has been mounting interest in the role of AR in breast cancer following identification of a subgroup (~12%) that lack expression of ERα but are AR+ and display features reminiscent of prostate cancers (2, 3) . However, the large majority (>70%) of breast cancers express both sex hormone receptors, and the role of AR in ERα+ breast cancer may be anti-estrogenic and thereby tumor suppressive (4) .
Inactivation and disposal of steroids regulates target cell exposure to steroid receptor agonists, and derangement of these pathways is evident in the pathology of hormone-dependent cancers (5, 6) . Several enzymatic pathways inactivate steroids, but glucuronidation is the only irreversible event. Uridine 5'-diphospho (UDP) glucuronosyltransferases (UGTs) create steroid conjugates incapable of binding to cognate receptors. The resulting steroid glucuronides are more hydrophilic and more readily excreted from tissues than unconjugated steroids. Therefore, glucuronidation is a vital mechanism that regulates steroid receptor activity within hormone responsive tissues. Metabolism of estrogenic hormones has been widely investigated in breast cancer (6) , but metabolism of androgenic hormones has yet to be extensively investigated in relation to this disease.
Among 19 human UGTs, only a few glucuronidate sex steroids to any significant extent (7, 8) . The most potent natural androgens, testosterone (T) and 5α-dihydrotestosterone (DHT) are glucuronidated by UGT2B15 and UGT2B17. Testosterone is a major precursor for synthesis Hence, the activity of UGT2B15 and UGT2B17 functionally impacts ERα and AR activity, but the significance of UGT2B15 and UGT2B17 expression has not been examined in relation to the different molecular subtypes and clinical outcomes of breast cancer.
Primary breast tissues express UGT2B15 and UGT2B17 (9) , with evidence of transcriptional up-regulation by ERα signaling in breast cancer cell lines (10, 11) . One study also reported that DHT weakly stimulated expression of these genes in an ERα-dependent manner (10) . The latter finding is feasibly due to metabolism of DHT into 3α-androstanediol (3α-diol) or 3β-androstanediol (3β-diol), compounds that have some estrogenic activity (12) , but this has not been tested. Finally, regulation of UGT2B15 and UGT2B17 by AR signaling has not been thoroughly investigated in an ERα-positive context and never in an AR+, ERα-negative breast cancer context, in which the consequences of androgen metabolizing capacity may markedly differ. The present study was undertaken to fill these gaps in knowledge by examining expression in large clinical cohorts and elucidating mechanisms of transcriptional regulation by sex steroid receptor signaling in breast cancer, taking into account the molecular complexity of this disease.
MATERIALS AND METHODS

Chemicals and Cell Culture
Steroids and steroid receptor antagonists were purchased from Sigma-Aldrich (Australia), including 17β-estradiol (E2), 5α-dihydrotestosterone (DHT), 5α-androstane-3α,17β-diol (3α-diol), 5α-androstane-3β,17β-diol (3β-diol), methyltrienolone (R1881), 4-hydroxy-flutamide 
Clinical Tissues and Ex Vivo Culture
Normal breast tissues from reduction mammoplasties were obtained from Flinders Medical Centre (Adelaide, Australia). Primary ERα-positive breast tumor samples were obtained from the Burnside Private Hospital (Adelaide, Australia). All tissues were collected after provision of informed, written consent by the donors. This study was approved by the University of Adelaide Human Research Ethics Committee (approval numbers: H-065-2005; H-169-2011). Tissue pieces were cultured on hydrated gelatine sponges (3-4 per sponge) as previously described (13, 14) . After a 36-hr pre-incubation period, hormones were added to the media as indicated and tissues harvested 24-hr later for RNA extraction. Representative pieces of uncultured tissue were fixed in 4% formalin in phosphate-buffered saline (PBS) at 4°C overnight then processed into paraffin blocks. Sections (2 µm) were: a) stained with haematoxylin and eosin and examined by a pathologist to quantify the relative proportion of tumor cells and b) immunostained for ERα and AR, as previously described (14) . Treatment conditions included: vehicle (0.01% ethanol), E2 (10 nM), DHT (10 nM), Enobosarm (100 nM).
RNA Extraction and Transcriptional Analyses
Research. Cell lines were cultured for 3 days in phenol red-free medium supplemented with 5% dextrancoated charcoal (DCC)-stripped FBS then seeded under the same conditions into six-well plates at 5 x 10 5 cells/well. Three days later, cells were treated for 24 h with treatments as indicated.
RNA extraction, reverse transcription and quantitative real-time PCR (RT-qPCR) was performed as previously reported (11, 15, 16) . For tissue samples, replicate pieces representing one condition were snap frozen in one tube containing RNAlater (Qiagen) and RNA isolated using RNeasy kits (Qiagen) according to manufacturer's protocol. Reverse transcription was performed using total RNA (500ng-1µg) and an iScript cDNA Synthesis Kit (Bio-Rad). The resulting cDNA was diluted 1:10 and used for transcriptional analysis as above.
Testosterone Glucuronidation Assay
MCF7 cells were pre-cultured for 72 hours in phenol red-free RPMI 1640 supplemented with 5% DCC-FBS in T175 flasks (Gibco) then treated with vehicle control (0.01% ethanol), E2 (10 nM), DHT (10 nM), 3α-diol (100 nM), or 3β-diol (100 nM) for 72 hours. Cells were scraped from flasks and whole cell lysates prepared in TE buffer (10 nM Tris-HCl and 1 mM EDTA, pH 7.6). Protein concentration was determined by Bradford assay (Bio-Rad), according to the manufacturer's protocol. The testosterone glucuronidation assay was conducted as previously reported (17) .
Luciferase Reporter Assays
MCF7 cells were plated into 96-well dishes in 100μl of phenol red-free RPMI 1640 supplemented with 5% DCC-FBS and cultured for 24-48 h prior to transfection. Cells were transfected with wild type or mutated UGT2B15 or UGT2B17 promoter constructs, treated with hormones as indicated and assessed for luciferase activity as previously described (11, 15) .
Research. Promoter construct details are provided in Suppl Methods. Transfections were performed in triplicate, and experiments repeated at least twice.
Electrophoretic Mobility Shift and Supershift Assays (EMSAs)
MCF7 cells were cultured in T75 flasks for 6 days in phenol red-free RPMI 1640 supplemented with 5% DCC-FBS then treated overnight (~16 h) with 0.1% ethanol (vehicle), E2 (10 nM), DHT (10 nM), 3α-diol (100 nM), or 3β-diol (100 nM). Nuclear extracts were prepared and EMSAs performed as previously reported (11, 18) . Probe and antibody information is provided in Supplemental Methods. 
Small
Chromatin Immunoprecipitation (ChIP) Experiments
Standard methodologies were employed as described previously for ChIP followed by RT-qPCR (11) and for ChIP followed by exonuclease digestion and deep sequencing (ChIP-exo) (19) . 
Statistical Analyses:
Log transformed data met the assumption of equal variance at a significance level of less than 0.01 (Levene's test). Analyses of transformed data were conducted by one-or two-way analysis of variance with the Tukey's post hoc test or independent t test using SPSS software (IBM, version 22). P < 0.05 was considered statistically significant. Recursive partitioning was used to dichotomize the METABRIC transcriptional data to assess the influence of relatively high versus low expression of each gene on patient survival using an R statistical language program as previously implemented (2) . This was performed for all probes representing a gene.
RESULTS
Expression of UGT2B15 and UGT2B17 in clinical breast cancers
The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) investigated 2,000 cases of breast cancer and redefined this heterogeneous disease into 10 molecular subgroups with distinct survival outcomes (2) . The subgroups, called iClusters, were created by an integration of gene copy number variations and cis-acting transcriptomes (20, 21) . Analysis of the microarray probes representing UGT2B15 and UGT2B17 in the METABRIC cohort revealed cases that displayed very high expression of these genes (Fig. 1A) . Their expression was positively correlated in this (Suppl. Fig 1A) as well as an independent breast cancer cohort (n = 825 cases) from The Cancer Genome Atlas (TCGA) (22, 23) (Suppl. Fig 1B) .
In the METABRIC cohort, ERα+ cases had significantly higher expression of these genes compared to ERα-negative cases (Fig. 1B) , and highest expression was observed in integrative cluster 1 (iCluster 1), predominantly comprised of ERα+, luminal B breast cancers (Fig. 1C) . Integrative cluster 10, largely comprised of aggressive, triple negative breast cancers, had the lowest expression (Fig. 1C) . Transcript levels of both enzymes significantly decreased with increasing
Research. tumor grade (Fig. 1D ). Higher levels of UGT2B17 were significantly associated with increased survival outcomes in cases classified into iCluster 5, largely comprised of high-grade breast cancers with HER2 amplification and very poor survival outcomes, as well as all cases in the cohort classified as being HER2 amplified by SNP6 array analysis (Fig. 1E ). Note that these groups contain both ERα+ and ERα-negative breast cancers. Higher levels of both UGT2B15 and UGT2B17 were associated with increased survival in iCluster 6 ( Fig. 1F) , dominated by ERα+, HER2-negative breast cancers with amplification of the 8p12 gene locus. Conversely, higher levels of UGT2B15 were associated with poor survival in iCluster 9, comprised of ERα+ cancers with a luminal B phenotype and a high rate of TP53 mutations (Fig. 1G ). We also analyzed the relationship between expression of these genes and patient outcome in another publically available resource (KMplotter) containing normalized microarray data from multiple studies that collectively represent 3,455 cases of breast cancer (24) . At present, this cohort can only be interrogated via the older PAM50 gene classifier. A high level of UGT2B15 expression was associated with improved relapse-free survival in the entire cohort and in all PAM50 subgroups (Suppl. Fig. 2 , upper row). While high UGT2B17 expression was also associated with improved relapse-free survival in the entire cohort, this association was only sustained in the luminal B and HER2+ subtypes (Suppl. Fig. 2 , lower row), the latter supporting results in Fig 1E . Collectively, these data suggest that expression of UGT2B15 or UGT2B17 impacts breast cancer survival in a gene-and disease subtype-specific manner. As expected, E2 significantly increased transcripts of UGT2B15 and UGT2B17 ( Fig. 2A-B ) and an ERα-regulated positive control gene (GREB1; Suppl. Fig. 3A ), effects that were abolished by co-treatment with fulvestrant (ICI), an ERα inhibitor. Treatment with DHT or its metabolites, 3α-diol or 3β-diol, dose-dependently increased UGT2B15 and UGT2B17 transcripts ( Fig. 2A-B ) and the control gene (Suppl. Fig 3A) to varying degrees. These stimulatory effects were all significantly attenuated by co-incubation with fulvestrant, supporting the hypothesis that DHT indirectly stimulates ERα activity via conversion to diols. Individual hormone treatments also significantly increased levels of glucuronidated testosterone (Fig 2C) , indicative of enhanced enzyme activity. Surprisingly, fulvestrant also inhibited the activity of R1881 (Fig 2A-B) , a synthetic androgen that is not metabolized to estrogenic compounds, although direct binding of R1881 to ERα at high doses has been reported (25) . While this data collectively suggested lack of direct regulation by AR, subsequent analyses revealed that the stimulatory effects of DHT were also significantly attenuated by treatment with flutamide, an AR antagonist (Suppl Fig 3B) and treatment with the ERα and AR inhibitors combined resulted in greater inhibition of steroidmediated up-regulation of UGT2B15 and UGT2B17 than either inhibitor alone (Fig. 2D ). These complementary effects were not evident for regulation of GREB1 by DHT, which was completely dependent on ERα (Suppl Fig 3C) . Consistent with a direct role for AR in upregulating the UGT genes, siRNA-mediated ablation of AR in MCF7 cells significantly reduced both E2-and DHT-mediated transcriptional effects (Fig 2E) . The same patterns of hormone regulation and the influence of AR loss were evident for the UGT2B15 gene in ZR75-1 cells, another model of ERα+AR+ breast cancer (Suppl Fig 3D) 
Steroid-induced transactivation of the proximal promoters of UGT2B15 and UGT2B17
Highly conserved estrogen response units (ERUs) reside in the proximal promoters of the UGT2B15 and UGT2B17 genes, comprised of three estrogen response element (ERE) half sites and two AP-1 binding sites, all required for E2-mediated transcriptional regulation (11) . A FOXA1 binding site has recently been identified in the region between two of the ERE half sites (11, 16) but its importance in breast cancer cells is unknown. The prototypical ERU, including the FOXA1 binding site, is depicted in Fig. 3A . As expected, E2 significantly enhanced basal promoter activity in an ERα-dependent manner ( Fig 3B) . All other steroids including DHT, 3α-diol, 3β-diol, and R1881 stimulated UGT2B15 promoter activity at levels similar to or greater than that induced by E2, and these stimulatory effects were all significantly repressed to some degree by the ERα inhibitor. However, the AR inhibitor also significantly reduced DHT-induced promoter activity (Fig. 3C ), supporting direct regulation by both sex steroid receptors.
An ERU mutant UGT2B15 promoter construct dramatically reduced transactivation by E2 and obliterated transactivation by other tested steroids (Fig 3D; left panel) and mutation of the FOXA1 site abolished all steroid-induced promoter activity (Fig 3D; right panel) .
Transactivation of the wild type ( Fig. 3E ; left panel) and FOXA1-mutated ( Fig. 3E; right panel) UGT2B17 promoter constructs by steroids mirrored that of the UGT2B15 constructs, but with more attenuated stimulatory effects.
To confirm the direct involvement of FOXA1, EMSA assays were performed. A major protein/DNA complex formed on a DNA probe containing the UGT2B15 promoter FOXA1 site following incubation with nuclear extracts from vehicle and steroid-treated MCF7 cells (Fig 4A) .
Research. Addition of a FOXA1 antibody reduced the intensity of the complex and also induced formation of super-shifted complexes. Furthermore, mutation of the FOXA1 site abolished the formation of FOXA1 protein/DNA complexes. Although the UGT2B15 and UGT2B17 gene promoters are highly conserved, a unique but prevalent -155A/G SNP occurs within the FOXA1 binding site in the UGT2B17 promoter (15) . Therefore, a UGT2B17 probe with an A-containing FOXA1 site was tested (Fig 4B) . A major complex was formed on the A-containing UGT2B17 FOXA1 probe, which was super-shifted by addition of FOXA1 antibody and abolished by mutating the FOXA1 site or adding a 100-fold molar excess of un-labelled probe. Therefore, endogenous FOXA1 in MCF7 cells can bind the "A-containing" FOXA1 binding site SNP in the UGT2B17 promoter.
These results confirm a critical role for FOXA1 in steroid-mediated transactivation of the UGT2B15 and UGT2B17 promoters, even in the context of a common SNP variant in UGT2B17.
Recruitment of ERα, FOXA1 and AR to the UGT2B15 and UGT2B17 promoters
ERα occupancy at the UGT2B15 and UGT2B17 proximal promoters and a positive control locus (pS2/TIF1) was significantly stimulated by E2 in MCF7 cells (Fig. 4C-E) . Of the other steroids tested, 3β-diol stimulated the highest level of ERα enrichment, a compound with significantly less affinity for ERα than E2 (26) . FOXA1 bound to the UGT2B15 and UGT2B17 loci before ligand stimulation, consistent with its role as a pioneer factor (27) . Interestingly, FOXA1 binding was significantly increased by all hormone treatments ( Fig. 4C-E) , contrary to observations at other genomic loci (28) . This steroid-induced increase in FOXA1 occupancy is consistent with a recent study showing that FOXA1 binding can be altered by activation of steroid receptors, including ERα, in breast cancer cells (29) . The AR did not display a strong enrichment over IgG controls under any treatment condition; maximal AR enrichment (2.6-fold) occurred at the positive control locus for ERα binding (pS2/TIFF1) when cells were stimulated with R1881.
Research. Low enrichment of AR may be a technical issue due to low AR protein levels in MCF7 cells.
However, the requirement for ERα, FOXA1, and AR in the regulation of UGT2B15 and UGT2B17 by steroids was confirmed by siRNA-mediated ablation (Suppl Fig 4) . Analysis of genome-wide ERα, FOXA1 and AR chromatin binding in MCF7 and ZR75-1 cells generated by ChIP-exo (19) revealed the presence of all three factors in the proximal promoters of the UGT genes (Figure 5A -B; magnified views in Suppl Fig 5) . ChIP-exo generates sharper peaks than ChIP-seq due to the inclusion of an exonuclease step following immunoprecipitation of protein-DNA complexes, allowing better discernment of relative binding positions. This data suggests that AR binds to or overlaps the ERE half site located 3' to the FOXA1 and ERα peaks in the promoters of UGT2B15 and UGT2B17. The tandem pattern of chromatin binding strongly supports the concept that ERα, AR and FOXA1 interact to regulate transcription of these two androgen inactivating enzymes in an estrogen sensitive breast cancer context.
Regulation of UGT2B15 and UGT2B17 by Enobosarm, a new selective AR modulator
Enobosarm (GTx024) is a selective AR modulator (SARM) (30) currently being tested for clinical efficacy in women with ERα+AR+ breast cancer (NCT02463032). This compound dosedependently activated an AR reporter construct transfected into MCF7 cells (Suppl Fig 6A) , upregulated UGT2B15 and UGT2B17 in an AR-dependent manner (Suppl Fig6B) and dosedependently increased activation of the wild type UGT promoter constructs (Fig 5C) . Using selective ERE mutant constructs of the UGT2B15 promoter, we show that the previously defined "3' ERE half site" is critical for AR-mediated up-regulation of promoter activity (Fig 5D) . 
also has similarities to prostate cancer (3). Interrogation of our previously published ChIP-seq data (31) shows that AR and FOXA1 occupy the proximal promoter regions of UGT2B15 and UGT2B17 in MDA-MB-453 cells, similar to ERα and FOXA1 occupancy in MCF7 cells and AR and FOXA1 occupancy in LNCaP prostate cancer cells (Fig. 6A-B) . However, treatment with DHT did not up-regulate expression of these genes in the MDA-MB-453 or MFM223 breast cancer cell lines (Fig 6C) , which both have a "luminal AR" phenotype (32) . UGT2B17 expression was undetectable under any treatment conditions in these AR+ ERα-negative cell lines. In contrast, DHT potently downregulates both genes in LNCaP cells (33) . Thus, while ERα and AR positively co-regulate transcription of the two major androgen metabolizing enzymes in an estrogen-sensitive breast cancer context, AR alone does not appear to have this capacity in an estrogen-insensitive context.
Estrogen and androgen regulation of UGT2B15 and UGT2B17 in clinical tissues
Normal breast tissue from reduction mammoplasties (n = 8) were cultured ex vivo on gelatin sponges to sustain tissue architecture, cellular heterogeneity and hormone receptor expression as previously described (14) . In 3/8 cases, all three treatments (E2, DHT, Enobosarm) up-regulated transcript levels of UGT2B15 or UGT2B17 compared to the vehicle control (Suppl Fig 6C) . In other cases, one or two agents demonstrated stimulatory action and in a few cases there were no effects, demonstrating the expected heterogeneity of primary tissue responses. This methodology also provides a unique pre-clinical model for testing drug responses (13, 34) . In primary ERα+ breast tumors (n = 13) cultured ex vivo under estrogenic conditions, treatment with Enobosarm up-regulated UGT2B15 in a total of 7/13 cases and UGT2B17 in 8/13 cases (Fig 7A-B) . Two Interrogation of that data revealed no evidence for ERα occupancy at the promoters of UGT2B15 or UGT2B17 in normal breast tissues (0/2 cases) or ERα+ tumors associated with a good outcome (0/8 cases). However, ERα occupancy was evident at the UGT2B15 (2/7 cases) and UGT2B17 (1/7 cases) promoters in tumors associated with poor outcomes and in 2/3 metastases (Fig. 7C-D) . Although the study represented a small number of cases, it was the first study to investigate genome-wide ERα chromatin interactions in clinical breast tissues.
DISCUSSION
Herein, the potential clinical significance and hormone-mediated regulation of two steroid glucuronidation enzymes, UGT2B15 and UGT2B17, was investigated in relation to breast cancer.
These enzymes can functionally impact both ERα and AR activity by directly or indirectly reducing levels of their activating ligands in the tissue microenvironment. While positive regulation of these genes via ERα activity at their proximal promoters has been previously described in breast cancer cell lines (10, 11), we provide the first evidence that this activity is exquisitely dependent on the pioneer factor FOXA1, is facilitated by AR binding to an adjacent ERE half site, and is potently stimulated by metabolites of DHT normally considered 'weak' In breast malignancies, the levels of estrogenic or androgenic hormones can greatly exceed levels measured in plasma or in adjacent non-malignant breast tissues (36, 37) . The altered intracrinology involves deregulation of steroid metabolizing genes such as 17β-HSDs, sulfotransferases (SULTs), 5α-reductases and estrogen metabolizing UGTs (38) (39) (40) . Our data indicate that androgen metabolizing UGTs are also involved, particularly in the context of ERα-positive and/or HER2-positive clinical breast cancers in which relative expression of UGT2B15 and/or UGT2B17 could discern cases with distinct survival outcomes. While it is tempting to speculate on how relative levels of either enzyme influences steroid intracrinology and hence disease outcome in various breast cancer contexts, it is important to note that UGT2B15 and enzymes in the glucuronidation of androgens or other compounds may explain gene-specific influences on breast cancer outcomes. We recently found that tamoxifen and its metabolites upregulate UGT2B15 via a mechanism involving ERα (45), which may have implications for resistance to this drug. Collectively, these studies indicate that the influence of UGT2B15 and UGT2B17 expression in breast cancer includes, but also has implications that extend beyond, their ability to metabolize androgen hormones.
Both metabolites of DHT (3α-and 3β-diol) could recruit ERα to the proximal promoters of UGT2B15 and UGT2B17 to stimulate transcription, which in part explains the ERα-dependent stimulatory effects of this androgen. Indeed, rapid conversion of DHT into 3α-and 3β-diol has been previously reported in MCF7 cells (46, 47) Research. 
